Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
patritumab (Daiichi Sankyo Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Patritumab is a fully human monoclonal IgG1 antibody directed against HER3 (human epidermal growth factor receptor-3). It inhibits ligand binding (heregulin alpha and heregulin beta) and receptor activation, and induces HER3 down-regulation. Functionally, patritumab inhibits tumor cell proliferation, survival, and anchorage-independent growth in vitro, and inhibits growth of HER3 expressing xenograft tumor models in vivo.
- Other names
- Anti-HER3 Monoclonal AntibodyAnti-HER-3 Monoclonal AntibodyAnti-HER 3 Monoclonal Antibody
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on patritumab (Daiichi Sankyo Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on patritumab (Daiichi Sankyo Co., Ltd.).